Gordon Debra B
University of Wisconsin Hospital and Clinics, Madison, USA.
Oncol Nurs Forum. 2006 Nov 3;33(2):257-64. doi: 10.1188/06.ONF.257-264.
PURPOSE/OBJECTIVES: To review the dose titration, efficacy, and safety of oral transmucosal fentanyl citrate (OTFC).
Phase I and II clinical trial abstracts and evidence-based review articles.
OTFC has an onset, peak, and duration of action similar to that of an IV dose of an opioid and has been demonstrated to be effective and well tolerated for the management of breakthrough pain in patients with cancer.
Studies of OTFC demonstrate that it is easy to use,noninvasive, effective, safe, and acceptable to patients, caregivers, and healthcare providers. However, OTFC is expensive and approved for use only in opioid-tolerant patients with cancer.
Breakthrough pain in patients with cancer is a common problem with characteristics that make it difficult to treat. Oncology nurses should familiarize themselves with OTFC's unique characteristics to be able to best help patients manage their therapy.
目的/目标：回顾口腔黏膜枸橼酸芬太尼（OTFC）的剂量滴定、疗效及安全性。
I期和II期临床试验摘要以及循证综述文章。
OTFC的起效、达峰及作用持续时间与静脉注射阿片类药物相似，且已证明对癌症患者爆发性疼痛的管理有效且耐受性良好。
OTFC的研究表明，它使用方便、无创、有效、安全，且患者、护理人员及医疗服务提供者均可接受。然而，OTFC价格昂贵，仅被批准用于耐受阿片类药物的癌症患者。
癌症患者的爆发性疼痛是一个常见问题，其特点使其难以治疗。肿瘤专科护士应熟悉OTFC的独特特性，以便能更好地帮助患者管理治疗。
